Verastem (VSTM) hosts its annual research and development day. Highlights: VSTM says it plans to have "three candidates in six clinical trials ongoing in parallel by the end of 2013"; Phase 1 portion of Phase 1/1b VS-6063 study is complete; "a significant decrease in the CA-125 biomarker in several patients" was observed; treatment is well tolerated in combination with paclitaxel, opening the door for exploring "this combination in a wide range of cancers."
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs